A group of US experts to evaluate Moderna’s vaccine as Europe promises vaccinations before the end of the year

American experts would discuss on Thursday whether Moderna’s Covid-19 vaccine should be authorized, as European nations have promised to start their coronavirus inoculation campaigns before the end of the year.

Spikes in infections have led to tighter restrictions in several European countries, while the United States, the most affected nation in the world, has set a double record, with more than 3,700 deaths and 250,000 new cases on Wednesday in the 24 hours.

With the US scrambling in its efforts to control the virus, Moderna’s vaccine is seen as a potential impetus in the fight against Covid-19 and the panel’s approval on Thursday could potentially pave the way for an all-out launch. start of next week.

“Recent news about vaccines has been very positive. However, significant challenges and uncertainties remain regarding the timing, production and distribution of vaccines, as well as their effectiveness across different groups,” said Jerome Powell, president of the Federal US Reserve. Wednesday.

“The continuing increase in new Covid-19 cases both here, in the United States and abroad is particularly concerning. And the next few months are likely to be very busy.”

Should speakers vote in favor of the Moderna vaccine, as widely expected, the Food and Drug Administration is likely to give the green light soon after, making the United States the first country to approve it.

The United States has already started vaccinating people with the Pfizer-BioNTech vaccine and hopes to have 20 million people immunized in December.

Healthcare professionals and long-term care residents are at the forefront and efforts are underway to convince the American public that vaccines are safe.

The White House announced Vice President Mike Pence and his wife will receive the vaccine on Friday at a public display, while a spokesman said President Donald Trump is “absolutely willing to get the vaccine.”

Since Trump recently recovered from a Covid-19 attack, he is currently thought to be immune.

Known global infections are rapidly approaching 74 million, with over 1.6 million deaths, and nations across Europe were battling spikes in Covid-19 numbers with fears of an explosion in cases over the Christmas period.

The spikes have resulted in tighter restrictions in many countries on the continent, which is approaching 500,000 deaths from the disease.

Denmark, France, Turkey and the Netherlands all tightened the curbs, while Germany began a new partial blockade on Wednesday to curb the spread of the virus.

“It feels like a Sunday,” said 57-year-old Ines Kumpl, observing the deserted streets of Berlin on the first day of a new partial blockade. “These measures are necessary but it is stressful.”

Germany said it will start vaccinations on December 27, a date that is expected to be matched across the European Union.

France said it will receive approximately 1.16 million doses of the vaccine by the end of the year, with an additional 2.3 million arriving in the next two months.

The pressure on the European Union has increased to speed up approvals since Britain and the United States began their immunization programs with the Pfizer-BioNTech vaccine.

While much of the world waits for a chance, Twitter said it would crack down on fake posts and vaccine conspiracy theories.

The policy will include actions against claims – submitted without any evidence – that the vaccine is used to intentionally cause harm or control people.

Virus-skeptical Brazilian president Jair Bolsonaro made a turnaround on Wednesday while supporting the nationwide mass immunization campaign.

His support came the day after he told a well-known TV presenter: “I’m not going to get vaccinated. It’s my problem. Period.”

While wealthier nations have managed to secure large numbers of doses, there are concerns that poorer nations may not have access anytime soon.

Peru, which has one of the highest Covid-19 death rates in the world, has admitted that it has no idea when it would be able to get hold of the researched vaccine stocks.